AU2001255798A1 - Glucagon antagonists - Google Patents
Glucagon antagonistsInfo
- Publication number
- AU2001255798A1 AU2001255798A1 AU2001255798A AU5579801A AU2001255798A1 AU 2001255798 A1 AU2001255798 A1 AU 2001255798A1 AU 2001255798 A AU2001255798 A AU 2001255798A AU 5579801 A AU5579801 A AU 5579801A AU 2001255798 A1 AU2001255798 A1 AU 2001255798A1
- Authority
- AU
- Australia
- Prior art keywords
- glucagon antagonists
- glucagon
- antagonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000051325 Glucagon Human genes 0.000 title 1
- 108060003199 Glucagon Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
- 229960004666 glucagon Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20143600P | 2000-05-03 | 2000-05-03 | |
US60/201,436 | 2000-05-03 | ||
US09/847,249 US6677136B2 (en) | 2000-05-03 | 2001-05-02 | Glucagon antagonists |
US09/847,249 | 2001-05-02 | ||
PCT/US2001/014321 WO2001083527A2 (en) | 2000-05-03 | 2001-05-03 | Glucagon antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001255798A1 true AU2001255798A1 (en) | 2001-11-12 |
Family
ID=26896746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001255798A Abandoned AU2001255798A1 (en) | 2000-05-03 | 2001-05-03 | Glucagon antagonists |
Country Status (5)
Country | Link |
---|---|
US (1) | US6677136B2 (en) |
EP (1) | EP1278772A2 (en) |
JP (1) | JP2003531632A (en) |
AU (1) | AU2001255798A1 (en) |
WO (1) | WO2001083527A2 (en) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7562012B1 (en) * | 2000-11-03 | 2009-07-14 | Audible Magic Corporation | Method and apparatus for creating a unique audio signature |
JP2006514932A (en) * | 2002-11-25 | 2006-05-18 | ジェネンコー・インターナショナル・インク | Peptides that bind to skin or hair |
US20050124550A1 (en) * | 2003-06-18 | 2005-06-09 | Peri Krishna G. | Compounds that modulate the glucagon response and uses thereof |
US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
BRPI0406605B8 (en) | 2003-11-13 | 2021-05-25 | Hanmi Holdings Co Ltd | protein conjugate, method for its preparation and pharmaceutical composition to enhance the duration and in vivo stability of a physiologically active polypeptide |
US20050222040A1 (en) * | 2004-04-05 | 2005-10-06 | Blm Group, Inc. | Vertebrate peptide modulators of lipid metabolism |
US20190330295A1 (en) * | 2005-05-04 | 2019-10-31 | Zealand Pharma A/S | Glucagon-like-peptide-2 (glp-2) analogues |
ES2507098T3 (en) | 2005-11-07 | 2014-10-14 | Indiana University Research And Technology Corporation | Glucagon analogs showing physiological solubility and stability |
EP2471810A1 (en) * | 2006-02-22 | 2012-07-04 | Merck Sharp & Dohme Corporation | Oxyntomodulin derivatives |
EP2124974B1 (en) * | 2007-01-05 | 2017-03-15 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers |
US8454971B2 (en) * | 2007-02-15 | 2013-06-04 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
JP5771005B2 (en) * | 2007-10-30 | 2015-08-26 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | Glucagon antagonist and compound showing GLP-1 agonist activity |
WO2009058662A2 (en) * | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Glucagon antagonists |
CN101983066B (en) * | 2008-01-30 | 2016-06-29 | 印第安那大学科技研究公司 | Insulin prodrug based on ester |
US8546327B2 (en) | 2008-06-17 | 2013-10-01 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
PL2300035T3 (en) * | 2008-06-17 | 2016-04-29 | Univ Indiana Res & Tech Corp | Gip-based mixed agonists for treatment of metabolic disorders and obesity |
JP5753779B2 (en) * | 2008-06-17 | 2015-07-22 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | Glucagon analogs with improved solubility and stability in buffers at physiological pH |
KR20110110174A (en) | 2008-12-19 | 2011-10-06 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | Amide based glucagon superfamily peptide prodrugs |
MX2011013625A (en) | 2009-06-16 | 2012-01-20 | Univ Indiana Res & Tech Corp | Gip receptor-active glucagon compounds. |
GB0917072D0 (en) * | 2009-09-29 | 2009-11-11 | Univ Ulster | Peptide analogues of glucagon for diabetes therapy |
WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
RU2012136450A (en) | 2010-01-27 | 2014-03-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | CONJUGATES GLUCAGON ANTAGONIST - GIP AGONIST AND COMPOSITIONS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY |
KR20130111923A (en) | 2010-05-13 | 2013-10-11 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | Glucagon superfamily peptides exhibiting g protein-coupled receptor activity |
CA2797095A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
CA2796894A1 (en) | 2010-06-24 | 2011-12-29 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
MA34885B1 (en) | 2010-12-22 | 2014-02-01 | Indiana Unversity Res And Technology Corp | GLUCAGON ANALOGS HAVING A GIP RECEPTOR ACTIVITY |
ES2968043T3 (en) | 2011-06-10 | 2024-05-06 | Hanmi Science Co Ltd | New oxyntomodulin derivatives and pharmaceutical composition for the treatment of obesity comprising the same |
KR101577734B1 (en) * | 2011-06-17 | 2015-12-29 | 한미사이언스 주식회사 | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
LT2723367T (en) | 2011-06-22 | 2017-08-25 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
CN103748109A (en) | 2011-06-22 | 2014-04-23 | 印第安纳大学研究及科技有限公司 | Glucagon/glp-1 receptor co-agonists |
WO2013004983A1 (en) * | 2011-07-04 | 2013-01-10 | Imperial Innovations Limited | Novel compounds and their effects on feeding behaviour |
WO2013056852A1 (en) * | 2011-10-21 | 2013-04-25 | Noxxon Pharma Ag | Glucagon binding nucleic acids |
WO2013074910A1 (en) | 2011-11-17 | 2013-05-23 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
RU2015101697A (en) | 2012-06-21 | 2016-08-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | GLUCAGON ANALOGUES WITH GIP RECEPTOR ACTIVITY |
KR101968344B1 (en) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | A composition for treating hyperlipidemia comprising oxyntomodulin analog |
SG11201503370WA (en) | 2012-11-06 | 2015-05-28 | Hanmi Pharm Ind Co Ltd | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
KR101993393B1 (en) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | A composition for treating diabetes or diabesity comprising oxyntomodulin analog |
RU2678134C2 (en) | 2013-03-14 | 2019-01-23 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Insulin-incretin conjugates |
TWI802396B (en) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease |
US10232020B2 (en) | 2014-09-24 | 2019-03-19 | Indiana University Research And Technology Corporation | Incretin-insulin conjugates |
MY185334A (en) | 2014-12-30 | 2021-05-06 | Hanmi Pharm Ind Co Ltd | Glucagon derivatives with improved stability |
KR102418477B1 (en) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | Gluagon Derivatives |
BR112017028517A2 (en) | 2015-06-30 | 2018-08-28 | Hanmi Pharm. Co., Ltd. | "pharmaceutical composition, vector, peptide, polynucleotide and isolated conjugate and composition" |
AU2016382394B2 (en) | 2015-12-31 | 2019-07-04 | Hanmi Pharm. Co., Ltd. | Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist |
TWI757305B (en) | 2016-06-29 | 2022-03-11 | 南韓商韓美藥品股份有限公司 | Glucagon derivative, a conjugate thereof, and a composition comprising the same, and a therapeutic use thereof |
EP3842061A1 (en) * | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Stapled triazole co-agonists of the glucagon and glp-1 receptors |
EP3842449A1 (en) * | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Stapled olefin co-agonists of the glucagon and glp-1 receptors |
WO2022047517A1 (en) * | 2020-09-04 | 2022-03-10 | Florey Institute For Neuroscience And Mental Health | Derivatisation of peptides and proteins |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
NL8720442A (en) | 1986-08-18 | 1989-04-03 | Clinical Technologies Ass | DELIVERY SYSTEMS FOR PHARMACOLOGICAL AGENTS. |
US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
US5408037A (en) | 1991-01-17 | 1995-04-18 | Zymogenetics, Inc. | Methods for detecting glucagon antagonists |
US5733731A (en) | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
CA2118130A1 (en) | 1992-04-14 | 1993-10-28 | Jean M. J. Frechet | Dendritic based macromolecules and method of production |
US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
US5349001A (en) | 1993-01-19 | 1994-09-20 | Enzon, Inc. | Cyclic imide thione activated polyalkylene oxides |
US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
US5480867A (en) | 1993-12-29 | 1996-01-02 | The Rockefeller University | Glucagon analogs with serine replacements |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US6184201B1 (en) * | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US6121022A (en) * | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
AU4474497A (en) | 1996-10-08 | 1998-05-05 | U-Bisys B.V. | Methods and means for selecting peptides and proteins having specific affinity for a target |
PL194159B1 (en) | 1996-12-20 | 2007-05-31 | Amgen Inc | Fusion-type protein ob - compositions and methods |
JP2003516150A (en) * | 1999-12-08 | 2003-05-13 | ジェンセット | Full-length human cDNA encoding a cryptic secretory protein |
-
2001
- 2001-05-02 US US09/847,249 patent/US6677136B2/en not_active Expired - Fee Related
- 2001-05-03 JP JP2001580951A patent/JP2003531632A/en not_active Withdrawn
- 2001-05-03 WO PCT/US2001/014321 patent/WO2001083527A2/en active Search and Examination
- 2001-05-03 AU AU2001255798A patent/AU2001255798A1/en not_active Abandoned
- 2001-05-03 EP EP01929003A patent/EP1278772A2/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US20030032588A1 (en) | 2003-02-13 |
JP2003531632A (en) | 2003-10-28 |
WO2001083527A2 (en) | 2001-11-08 |
US6677136B2 (en) | 2004-01-13 |
WO2001083527A3 (en) | 2002-08-01 |
EP1278772A2 (en) | 2003-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001255798A1 (en) | Glucagon antagonists | |
AU2002365622A1 (en) | Novel glucagon antagonists | |
AU2002341834A1 (en) | Antagonists | |
AU2001274288A1 (en) | Centraliser | |
AU2001274302A1 (en) | Centraliser | |
DZ3293A1 (en) | Substituted arylpyrazines | |
AU2000267458A1 (en) | Hypercomputer | |
AU2001254546A1 (en) | Aminopiperidines | |
AU2002223501A1 (en) | Glucagon antagonists/inverse agonists | |
AU6227101A (en) | Substituted iminoazines | |
AU2001239310A1 (en) | Decahydro-isoquinolines | |
AU2001220246A1 (en) | Neckphone | |
AU2002223500A1 (en) | Glucagon antagonists/inverse agonists | |
AU2001237637A1 (en) | Centraliser | |
AU2001264657A1 (en) | Crf receptor antagonists | |
AU2001234741A1 (en) | Integrin antagonists | |
AU2003291959A1 (en) | Novel glucagon antagonists | |
AU2001239773A1 (en) | Baroplastic materials | |
AU2001265871A1 (en) | Substituted sulfonylaminopyrimidines | |
AU2001254731A1 (en) | Substituted phenyluracils | |
AU2001258255A1 (en) | Substituted benzoylcyclohexenones | |
AU5825501A (en) | Substituted benzoylcyclohexenones | |
AU2001276354A1 (en) | Hetaryl-substituted heterocycles | |
AU2001271018A1 (en) | Gpr14 antagonist | |
AU2001295398A1 (en) | Endothelin antagonist |